Detection of Antiphosphatidylserine/Prothrombin Antibodies and Their Potential Diagnostic Value

Table 2

Antiphospholipid antibodies and LA in a relationship to arterial thrombosis (AT), venous thrombosis (VT), and obstetric complications (OC).

Antibody	Arterial thrombosis (41)
		No.	𝑃 value	Odds ratio (95% Cl)	Sensitivity %	Specificity %
LA		17	0.43	1.4 (0.6–2.9)	49	59
aCL	IgG	34	<0.001	5.5 (2.3–13.4)	83	53
	IgM	6	0.67	1.2 (0.4–3.5)	15	88
Anti-𝛽2GPI	IgG	26	0.02	2.4 (1.2–5.1)	63	58
	IgM	5	0.99	1.0 (0.3–2.9)	12	88
In-house aPS/PT	IgG	18	0.08	1.9 (0.9–4.1)	44	71
	IgM	16	0.36	1.4 (0.6–2.9)	39	69
QUANTA Lite aPS/PT	IgG	17	0.03	2.3 (1.0–4.9)	41	77
	IgM	17	0.38	1.4 (0.7–2.9)	41	66
	LAC	26	0.50	1.3 (0.6–2.7)	62	43
	Venous thrombosis (53)
LA		31	<0.001	5.6 (2.6–12.2)	70	70
aCL	IgG	39	<0.005	3.0 (1.5–6.2)	74	52
	IgM	12	0.010	3.5 (1.3–9.2)	23	92
Anti-𝛽2GPI	IgG	35	<0.001	3.2 (1.6–6.5)	66	63
	IgM	10	0.070	2.5 (0.9–6.5)	19	91
In-house aPS/PT	IgG	27	<0.001	3.5 (1.7–7.0)	51	77
	IgM	24	0.021	2.2 (1.1–4.5)	45	73
QUANTA Lite aPS/PT	IgG	25	<0.001	4.0 (1.9–8.3)	47	82
	IgM	26	0.013	2.4 (1.2–4.7)	49	71
	LAC	37	0.043	2.1 (1.0–4.2)	70	47
	Obstetric complications (28)
LA		13	<0.005	4.3 (1.6–11.9)	62	73
aCL	IgG	22	<0.001	5.8 (2.1–15.9)	79	61
	IgM	6	0.130	2.5 (0.8–7.8)	21	90
Anti-𝛽2GPI	IgG	19	0.002	4.1 (1.7–10.4)	68	66
	IgM	5	0.278	2.0 (0.6–6.6)	18	90
In-house aPS/PT	IgG	18	<0.001	9.3 (3.5–24.6)	64	84
	IgM	15	<0.005	4.0 (1.6–9.9)	54	78
QUANTA Lite aPS/PT	IgG	14	<0.001	6.3 (2.4–16.7)	50	86
	IgM	16	<0.005	4.3 (1.7–10.6)	57	76
	LAC	21	0.042	2.7 (1.0–9.1)	75	48

aCL: anticardiolipin, anti-𝛽₂GPI: anti-𝛽₂glycoprotein, aPS/PT: anti-phosphatidylserine/prothrombin, LA: lupus anticoagulant, OR: odds ratio, and CI: confidence interval.